Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;75(5):755-766.
doi: 10.1111/his.13936. Epub 2019 Oct 3.

A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3

Tadashi Sakane  1   2 , Takayuki Murase  1 , Katsuhiro Okuda  2 , Kosuke Saida  1 , Ayako Masaki  1 , Takeshi Yamada  3 , Yushi Saito  4 , Ryoichi Nakanishi  2 , Hiroshi Inagaki  1
Affiliations

A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3

Tadashi Sakane et al. Histopathology. 2019 Nov.

Abstract

Aims: Thymic carcinoma is rare and usually has a fatal outcome. Gene mutations in the epidermal growth factor receptor (EGFR) signalling pathway and TP53 have not been well analysed in thymic carcinoma.

Methods and results: We examined a large cohort of thymic carcinoma and thymoma type A/B3 and looked for gene mutations in the RAS family, EGFR, PIK3CA, AKT1, BRAF and TP53. Among 54 thymic carcinoma cases, RAS family mutations were detected in 10 cases, EGFR in two, PIK3CA in one, AKT1 in one, BRAF in none and TP53 in five. Among 33 thymoma type A/B3 cases, HRAS gene mutation were found in one, PIK3CA in two and AKT1 in one. All these mutations were those of missense type activating mutations. RAS family mutations were significantly more frequent in thymic carcinoma than in thymoma type A/B3 (P = 0.0461). A prognostic analysis focusing on thymic squamous cell carcinoma cases (n = 44) showed that the overall survival was significantly shorter in patients with EGFR pathway mutations (n = 9) than in those without in a univariate analysis (P = 0.0173). Subsequently, EGFR pathway mutations were selected as an independent factor for a poor overall survival in a multivariate analysis (P = 0.0389).

Conclusions: Mutations in the EGFR pathway and TP53 in thymic carcinoma may be frequent, and the EGFR pathway mutations may be associated with a poor prognosis in thymic squamous cell carcinoma patients. The therapeutic significance of gene mutations in thymic carcinoma should be further clarified.

Keywords: EGFR pathway gene; TP53 gene; mutations; thymic carcinoma; thymoma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Engels EA. Epidemiology of thymoma and associated malignancies. J. Thorac. Oncol. 2010; 5; S260-S265.
    1. de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur. J. Cancer 2008; 44; 123-130.
    1. Travis WD, Brambilla E, Burke AP et al. eds. WHO classification of tumours of lung, pleura, thymus and heart. 4th ed. Lyon: IARC, 2015.
    1. Nenninger R, Schultz A, Hoffacker V et al. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab. Invest. 1998; 78; 743-753.
    1. Kadota Y, Okumura M, Miyoshi S et al. Altered T cell development in human thymoma is related to impairment of MHC class II transactivator expression induced by interferon-gamma (IFN-gamma). Clin. Exp. Immunol. 2000; 121; 59-68.